Treatment with GnRH-AIF chimeric proteins reduced the viability of CRC organoids in a dose-dependent manner, reaching an 80% reduction in the organoids’ viability at the highest concentration tested (Figure 9B,C). This evidence concerns the gene GNRH1 and colorectal carcinoma.